Group 1 - The Chinese medicine (core stocks) sector experienced a significant rise, with notable increases in stock prices for companies such as Zhendong Pharmaceutical (+19.16%) and Shengwugu (+13.86%) [1][2] - The Ministry of Industry and Information Technology and seven other departments recently issued the "Implementation Plan for the High-Quality Development of the Chinese Medicine (Core Stocks) Industry (2026-2030)", aiming to establish a collaborative development system for the entire industry chain by 2030 [2][3] Group 2 - The plan outlines six major actions, including improving raw material quality and supply, enhancing manufacturing capabilities, and promoting the revitalization of the national medicine industry, with 15 specific tasks to be implemented [3] - The initiative aims to cultivate 60 high-standard Chinese medicine raw material production bases and support the establishment of 10 major traditional Chinese medicine varieties, while also promoting innovation in Chinese medicine products [3][4] Group 3 - Companies involved in the planting and processing of Chinese medicinal materials are expected to benefit from the establishment of high-standard production bases and the development of modern seed industries, leading to standardized and large-scale growth opportunities [4] - Firms focusing on innovative research and development in Chinese medicine will gain from the encouragement of AI and big data technologies, which will facilitate the transformation of classic formulas into innovative drugs [4][5] Group 4 - The plan includes the construction of 20 smart factories and 10 green factories, which will enhance production efficiency and product quality through digital transformation [4][5] - Companies like Te Yi Pharmaceutical and Hongri Pharmaceutical are positioned to benefit from the promotion of traditional Chinese medicine products and the digitalization of manufacturing processes, respectively [6]

Industry Overview - The gynecological medication industry encompasses drugs for the prevention, diagnosis, and treatment of gynecological diseases, including traditional hormone therapies, antibiotics, analgesics, and immunomodulators [1][3] - The market for gynecological medications in China has shown rapid growth, with the market size increasing from 27.735 billion yuan in 2012 to an estimated 56.137 billion yuan in 2024, reflecting a compound annual growth rate (CAGR) of 6.05% [1][9] - By 2025, the market size is projected to reach approximately 59.53 billion yuan, driven by increasing awareness of women's health and societal emphasis on female health [1][9] Market Dynamics - The prevalence of gynecological diseases among adult women in China is high, with an estimated incidence rate between 40% and 70%, including conditions such as tumors, cysts, reproductive-related diseases, and gynecological inflammation [6] - The rise in gynecological disease rates and the growing health consciousness among women are contributing to the steady expansion of the gynecological medication market [6] Industry Chain - The gynecological medication industry chain consists of upstream raw materials, intermediates, and pharmaceutical equipment; midstream production; and downstream distribution through pharmacies, hospitals, and e-commerce platforms [6][7] Key Companies - Notable companies in the gynecological medication sector include Qianjin Pharmaceutical, Tongrentang, Kangyuan Pharmaceutical, Jiuzhitang, Yunnan Baiyao, and others, which are focusing on R&D and product differentiation [10][11] Development Trends - Future product development in gynecological medications is expected to shift towards precision and individualized treatment, utilizing diagnostic technologies to enhance treatment efficacy and reduce side effects [12] - Innovations in drug formulations and delivery methods will improve patient compliance and experience, with a focus on long-acting, user-friendly options [13] - The role of gynecological medication companies is evolving from mere drug suppliers to providers of comprehensive health management solutions for women throughout their life stages [14]

Group 1 - The market regulatory authority has intensified supervision in key livelihood areas such as healthcare, pharmaceuticals, medical devices, food, and children's myopia prevention, announcing ten typical cases of illegal advertising [1][2] - Guangzhou Jianmei Health Technology Co., Ltd. was fined 600,000 yuan for false advertising claims regarding children's eye health products, including "children's lutein" and "eye nose probiotics" [1] - Nala Zun Camel (Guangzhou) Dairy Co., Ltd. was fined 450,000 yuan for misleading claims in its advertising of "camel milk powder" related to disease prevention and treatment [1] - Inner Mongolia Caozhilou Biotechnology Co., Ltd. was fined 200,000 yuan for advertising "organic perilla seed oil" with claims of cancer prevention [1] Group 2 - Chongqing Linhui Tai Business Information Consulting Co., Ltd. was fined 160,000 yuan for advertising "986 germ life enzyme" and other products with false claims about treating serious diseases [2] - Hangzhou Qingbi Brand Management Co., Ltd. was fined 190,000 yuan for misleading claims in advertisements for various health products, including "myopia astigmatism lutein eye patches" [2] - Songyuan Anorectal Hospital was fined 100,000 yuan for false claims regarding its affiliation with reputable medical institutions, affecting public trust and safety [2] Group 3 - Yunnan Yuyao Biopharmaceutical Co., Ltd. was fined 100,000 yuan for violating advertising regulations by promoting a prescription drug, "Sanqi Fatty Liver Pill," inappropriately [3]

证券日报网讯1月26日，九芝堂（000989）在互动平台回答投资者提问时表示，根据公司《2025年半年 度报告》披露：中药经典名方YB106、YB107按项目研发计划正常推进。如有重大进展公司将根据信息 披露的相关规定进行公告。 ...

证券日报网讯1月26日，九芝堂（000989）在互动平台回答投资者提问时表示，公司积极关注国家各项 政策，各子公司经营及财务状况公司将在对外披露的年度报告及半年度报告中披露。后续如涉及应披露 事项，公司将及时履行信息披露义务。 ...

格隆汇1月26日丨九芝堂(000989.SZ)近日接受特定对象调研时表示，公司主要开展创新药抗凝一类新药 YB209 项目、创新型环脂肽类抗生素 YB211 项目的研发以及干细胞项目的研发。根据2025 年半年度报 告披露，公司研发中心YB209 项目完成免疫原性研究的方法开发和验证，完成 I 期临床收尾、关闭实验 中心；YB211 项目完成临床样品制备、2 段生殖毒性试验、PK-PD 启动，完成临床 I 期试验并全面启动 临床Ⅱ期试验，受试者入组等工作。目前，YB211 项目受试者入组及临床试验观测等工作正积极有序 开展。 ...

证券代码：000989 证券简称：九芝堂 九芝堂股份有限公司投资者关系活动记录表 Q4：公司生物药创新药研发进展如何？ 公司主要开展创新药抗凝一类新药 YB209 项目、创新型环 脂肽类抗生素 YB211 项目的研发以及干细胞项目的研发。根据 2025 年半年度报告披露，公司研发中心 YB209 项目完成免疫原 2 性研究的方法开发和验证，完成 I 期临床收尾、关闭实验中心； YB211 项目完成临床样品制备、2 段生殖毒性试验、PK-PD 启动， 完成临床 I 期试验并全面启动临床Ⅱ期试验，受试者入组等工 作。目前，YB211 项目受试者入组及临床试验观测等工作正积 极有序开展。 编号：2026001 投资者关系活 动类别 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称、 人员姓名、时间 2026 年 1 月 23 日：光大证券黄素青、民生加银刘浩、富国基 金黄致君、中意资产马成骥、兴全基金戴心、东吴基金吴佳歆 地点 九芝堂股份有限公司（北京） 上市公司接待 人员姓名 董事会秘书韩辰骁 投资者关系活 动主要内容介 ...

2026年1月22日，本公司董事会收到公司副总经理徐向平递交的书面辞职报告，因工作调整其申请辞去 公司副总经理职务，辞去前述职务后仍在公司工作。徐向平原定任期为2024年7月30日至第九届董事会 任期届满（即2027年7月29日），根据《公司章程》等相关规定，徐向平的辞职报告自送达公司董事会 之日起生效。 截至本公告披露日，徐向平持有公司股份114,000股，其所持有的公司股份将继续按照相关法律法规、 规范性文件的规定进行管理。徐向平不存在未履行完毕的公开承诺，将按公司相关制度做好工作交接， 其辞职不会影响公司正常的生产经营。 公司董事会对徐向平在任职期间的辛勤付出以及为公司发展所做出的贡献表示衷心感谢。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000989 证券简称：九芝堂 公告编号：2026-002 九芝堂股份有限公司 关于公司副总经理辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重 大遗漏。 特此公告。 九芝堂股份有限公司董事会 2026年1月23日 ...

（文章来源：证券日报） 证券日报网讯 1月22日，九芝堂发布公告称，2026年1月22日，公司董事会收到公司副总经理徐向平递 交的书面辞职报告，因工作调整其申请辞去公司副总经理职务，辞去前述职务后仍在公司工作。徐向平 原定任期为2024年7月30日至第九届董事会任期届满（即2027年7月29日），根据《公司章程》等相关规 定，徐向平的辞职报告自送达公司董事会之日起生效。 ...

南财智讯1月22日电，九芝堂公告，2026年1月22日，公司董事会收到公司副总经理徐向平递交的书面辞 职报告，因工作调整其申请辞去公司副总经理职务，辞去前述职务后仍在公司工作。徐向平原定任期为 2024年7月30日至第九届董事会任期届满，其辞职报告自送达公司董事会之日起生效。截至本公告披露 日，徐向平持有公司股份114,000股，其所持有的公司股份将继续按照相关规定进行管理。徐向平不存 在未履行完毕的公开承诺，将按公司相关制度做好工作交接。 ...